NeuroDerm Ltd. NDRM
NDRM exceeded all expectations yesterday after we caught it on an early morning news scan; it spent the entire day in full-on breakout mode setting records in both price and volume, trading almost 27X the norm over the six week period since the stock’s IPO.
Positive response to yesterday’s early morning press statement hurtled NDRM from an early low of 8.16 all the way up to 19.07 just prior to the close, making gains of up to 134% possible.
We’ll still be standing at the ready for an eventual course correction and chance for a dip-and-rip maneuver, but any way you slice it, NDRM is getting marked down as a huge winner. It’s a great way to close out what has, on the whole, been an absolutely stellar year.
NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease (Tue 7:00AM EST)
Precious Metals on Watch: Gold, Silver
GDX and SLV have each been maintaining higher highs and higher lows since reaching a bottom in November. As we head into the New Year, we’re going to devote a good amount of focus to gold and silver, and tracking these indices and their options chains is going to be a good way to do that.
In particular, we’re going to be monitoring a few specific sets of contracts for each play:
SLV – March $15-15.50 Calls
GDX – March $17.50-$18 Calls
As you can see from the side-by-side chart we drew up below, GDX and SLV are looking similarly ripe. We’ve got SLV breaking the 50-Line on the RSI, and GDX following closely behind in that regard, we’re seeing testing of the 50DMA’s on both charts, and each of the MACD’s are giving the indication of bullish crosses.
We’re also going to radar HMCP, a sub-penny momentum play that has had an interesting past few sessions.
NRX, RDHL, MIG, CYTK, NEON, BCLI, CVEO